These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33747739)

  • 1. Cytosolic Delivery of Thiolated Neoantigen Nano-Vaccine Combined with Immune Checkpoint Blockade to Boost Anti-Cancer T Cell Immunity.
    Zhang D; Lin Z; Wu M; Cai Z; Zheng Y; He L; Li Z; Zhou J; Sun L; Chen G; Zeng Y; Li J; Liu J; Yang H; Liu X
    Adv Sci (Weinh); 2021 Mar; 8(6):2003504. PubMed ID: 33747739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma.
    Lin Z; Jiang C; Wang P; Chen Q; Wang B; Fu X; Liang Y; Zhang D; Zeng Y; Liu X
    Theranostics; 2023; 13(12):4166-4181. PubMed ID: 37554274
    [No Abstract]   [Full Text] [Related]  

  • 3. Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy.
    Liang Z; Cui X; Yang L; Hu Q; Li D; Zhang X; Han L; Shi S; Shen Y; Zhao W; Ju Q; Deng X; Wu Y; Sheng W
    Int J Pharm; 2021 Oct; 608():121091. PubMed ID: 34555477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD16 CAR-T cells enhance antitumor activity of CpG ODN-loaded nanoparticle-adjuvanted tumor antigen-derived vaccinevia ADCC approach.
    Zhang X; Hu Q; He X; Cui X; Liang Z; Wang L; Deng X; Zhang Z; Sheng W; Han XD
    J Nanobiotechnology; 2023 May; 21(1):159. PubMed ID: 37208748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remodeling Tumor-Associated Neutrophils to Enhance Dendritic Cell-Based HCC Neoantigen Nano-Vaccine Efficiency.
    Wang Y; Zhao Q; Zhao B; Zheng Y; Zhuang Q; Liao N; Wang P; Cai Z; Zhang D; Zeng Y; Liu X
    Adv Sci (Weinh); 2022 Apr; 9(11):e2105631. PubMed ID: 35142445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion.
    D'Alise AM; Leoni G; De Lucia M; Langone F; Nocchi L; Tucci FG; Micarelli E; Cotugno G; Troise F; Garzia I; Vitale R; Bignone V; Di Matteo E; Bartolomeo R; Charych DH; Lahm A; Zalevsky J; Nicosia A; Scarselli E
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors.
    Du Y; Liu Y; Wang D; Bai H; Wang Z; He X; Zhang P; Tian J; Wang J
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer.
    Peng H; Li L; Zuo C; Chen MY; Zhang X; Myers NB; Hogg GD; DeNardo DG; Goedegebuure SP; Hawkins WG; Gillanders WE
    Front Immunol; 2022; 13():1039226. PubMed ID: 36569934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity.
    Liu L; Chen J; Zhang H; Ye J; Moore C; Lu C; Fang Y; Fu YX; Li B
    Nat Cancer; 2022 Apr; 3(4):437-452. PubMed ID: 35393580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.
    Liu CJ; Schaettler M; Blaha DT; Bowman-Kirigin JA; Kobayashi DK; Livingstone AJ; Bender D; Miller CA; Kranz DM; Johanns TM; Dunn GP
    Neuro Oncol; 2020 Sep; 22(9):1276-1288. PubMed ID: 32133512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy.
    Yazdani M; Gholizadeh Z; Nikpoor AR; Mohamadian Roshan N; Jaafari MR; Badiee A
    Sci Rep; 2021 Jul; 11(1):14661. PubMed ID: 34282215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoantigen Dendritic Cell Vaccination Combined with Anti-CD38 and CpG Elicits Anti-Tumor Immunity against the Immune Checkpoint Therapy-Resistant Murine Lung Cancer Cell Line LLC1.
    Sun C; Nagaoka K; Kobayashi Y; Nakagawa H; Kakimi K; Nakajima J
    Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG Oligodeoxynucleotide Developed to Activate Primate Immune Responses Promotes Antitumoral Effects in Combination with a Neoantigen-Based mRNA Cancer Vaccine.
    Li Q; Ren J; Liu W; Jiang G; Hu R
    Drug Des Devel Ther; 2021; 15():3953-3963. PubMed ID: 34566407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Engineered AAV-Based Neoantigen Vaccine in Combination with Radiotherapy Eradicates Tumors.
    Huang KC; Lai CY; Hung WZ; Chang HY; Lin PC; Chiang SF; Ke TW; Liang JA; Shiau AC; Yang PC; Chen WT; Chao KSC
    Cancer Immunol Res; 2023 Jan; 11(1):123-136. PubMed ID: 36315960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of neoantigen in immune checkpoint blockade therapy.
    Yi M; Qin S; Zhao W; Yu S; Chu Q; Wu K
    Exp Hematol Oncol; 2018; 7():28. PubMed ID: 30473928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Potent Micron Neoantigen Tumor Vaccine GP-Neoantigen Induces Robust Antitumor Activity in Multiple Tumor Models.
    Jing Z; Wang S; Xu K; Tang Q; Li W; Zheng W; Shi H; Su K; Liu Y; Hong Z
    Adv Sci (Weinh); 2022 Aug; 9(24):e2201496. PubMed ID: 35712770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines.
    Shae D; Baljon JJ; Wehbe M; Christov PP; Becker KW; Kumar A; Suryadevara N; Carson CS; Palmer CR; Knight FC; Joyce S; Wilson JT
    ACS Nano; 2020 Aug; 14(8):9904-9916. PubMed ID: 32701257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.